Previous 10 | Next 10 |
2023-10-31 11:23:44 ET More on Mersana Therapeutics Mersana Therapeutics: Still In 'Show Me' Territory Mersana Therapeutics appoints Martin Huber as CEO Seeking Alpha’s Quant Rating on Mersana Therapeutics Historical earnings data for Mersana Therapeut...
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that...
2023-10-14 00:11:02 ET Summary Mersana Therapeutics, a clinical-stage biotech company, suffered a major trial failure for its lead candidate in July, causing a significant drop in stock value. The company took immediate measures and laid off half of its staff and discontinued deve...
2023-09-06 07:52:02 ET More on Mersana Therapeutics Seeking Alpha’s Quant Rating on Mersana Therapeutics Historical earnings data for Mersana Therapeutics Financial information for Mersana Therapeutics Mersana: When Reality Bites, A Neutral Stance Prev...
Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of Directors Martin Huber, M.D., current member of the Board of Directors, to be named President and CEO Brian DeSchuytner named Chief Operating Officer; Mohan Bala, Ph.D., ...
2023-08-08 09:56:40 ET Mersana Therapeutics press release ( NASDAQ: MRSN ): Q2 GAAP EPS of -$0.47. Revenue of $10.65M (+148.8% Y/Y). For further details see: Mersana Therapeutics GAAP EPS of -$0.47, revenue of $10.65M
Organization fully focused on product candidates and collaborations based on next-generation ADC platforms Capital resources expected to support current operating plan commitments into 2026 CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: M...
2023-07-27 10:07:10 ET Gainers: Carmell Therapeutics ( CTCX ) +44% . Mallinckrodt ( MNK ) +35% . Evolus ( EOLS ) +28% . Lipocine ( LPCN ) +26% . Spok ( SPOK ) +23% . Losers: Mersana Therapeutics ( MRSN ) -77% . ...
2023-07-27 08:38:02 ET Mersana Therapeutics ( MRSN ) -74% announces topline data from UPLIFT clinical trial in patients with platinum-resistant Ovarian Cancer and strategic reprioritization. Biohaven ( BHVN ) -27% . Yellow Corporation ( YELL ) -26% . ...
UPLIFT clinical trial did not meet its primary endpoint Company realigns focus and significantly reduces expenses to extend cash runway into 2026 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...